Company Regulus Therapeutics Inc Nasdaq
Equities
US75915K1016
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Chief Tech/Sci/R&D Officer | - | 22-11-28 | |
Rekha Garg
LAW | General Counsel | - | 22-11-28 |
Amin Kamel
PRN | Corporate Officer/Principal | - | 22-06-01 |
Daniel Penksa
AUD | Comptroller/Controller/Auditor | 39 | 15-05-31 |
Christopher Aker
LAW | General Counsel | 63 | 11-05-18 |
Brian K. Campion
PRN | Corporate Officer/Principal | - | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 | |
Chairman | 74 | 07-12-31 | |
Jake Nunn
BRD | Director/Board Member | 54 | 19-06-10 |
Alice S. Huang
BRD | Director/Board Member | 85 | 21-01-25 |
Hugh Rosen
BRD | Director/Board Member | 64 | 16-06-01 |
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Director/Board Member | 56 | 18-04-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 3,725,720 | 0 | 0 | 95.99 % |
Stock B | 0 | 258,707 | 0 | 0 | |
Stock C | 0 | 1,330,832 | 0 | 0 | |
Stock D | 1 | 65,465,251 | 64,363,054 ( 98.32 %) | 0 | |
Stock E | 0 | 256,700 | 0 | 0 |
Company contact information
Regulus Therapeutics, Inc.
4224 Campus Point Court Suite 210
92121, San Diego
+858 202 6300
http://www.regulusrx.comSector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |